Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

Neuro-Oncology Advances(2021)10.1093/noajnl/vdab102Source: DataRank Database

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin is a research paper published in Neuro-Oncology Advances (2021). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 1.28)OA: goldTopics (23)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Sagun Parakh ORCID,Andrew B. Lassman ORCID,Aidan Seow,Eddie Lau ORCID,Sze Ting Lee ORCID

Live enrichment

PubMed:34549181 PMC:PMC8446913 OpenAlex:https://openalex.org/W3191916947

Cancer Council Victoria

Grant: 1164229

National Health and Medical Research Council

Grant: 1177837

National Institutes of Health

Grant: UM1 CA189960

National Institutes of Health

Grant: P30CA013696

National Institutes of Health

Grant: 5UG1CA189960-02

Columbia University Minority/Underserved Site NCI Community Oncology Research Program

National Institutes of Health

Grant: 3P30CA013696-21S1

CANCER CENTER CORE SUPPORT GRANT

National Cancer Institute

Australian Cancer Research Foundation

Victorian Cancer Agency

FWCI

1.28

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

goldLicense: cc-by

journalhttps://academic.oup.com/noa/article-pdf/3/1/vdab102/40404181/vdab102.pdf

publisherhttps://academic.oup.com/noa/article-pdf/3/1/vdab102/40404181/vdab102.pdf

publisherhttp://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdab102/39551145/vdab102.pdf

publisherhttp://academic.oup.com/noa/article-pdf/3/1/vdab102/40404181/vdab102.pdf

journalhttps://doi.org/10.1093/noajnl/vdab102

Fields of Study

Glioma Diagnosis and TreatmentHER2/EGFR in Cancer ResearchBrain Metastases and Treatment0301 basic medicine03 medical and health sciences0302 clinical medicine

Keywords

BiodistributionMedicineGlioblastomaInternal medicineVolume of distributionOncologyNuclear medicinePharmacokineticsPathologyIn vivoCancer researchBiologyTumor VolumeGbmDepatuxizumab MafadotinBasic and Translational Investigations610

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

FAIR Checklist

Authors (15)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)